Day: March 10, 2021

HOUSTON, March 10, 2021 (GLOBE NEWSWIRE) — W&T Offshore, Inc. (NYSE: WTI) (“W&T” or the “Company”) today announced that the Company will participate in the Virtual 33rd Annual ROTH Conference that will be held on March 15-17, 2021.Chairman and Chief Executive Officer Tracy W. Krohn and Executive Vice President and Chief Financial Officer, Janet Yang will host virtual one-on-one meetings with investors registered for the conference on March 16. A pre-recorded virtual presentation done by Mr. Krohn in conjunction with the event will be posted on W&T’s website, www.wtoffshore.com, in the “Investors” section of the site, on the “News and Events” page beginning on Thursday, March 11. An updated investor slide deck also prepared in conjunction with the ROTH Conference will be posted in the “Investors” section of W&T’s...

CRANBURY, N.J., March 10, 2021 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that the company will present at the American Association for Cancer Research (AACR) Annual Meeting 2021 taking place April 10-15, 2021.Details on the abstract and presentation can be found below.About p53p53 plays a pivotal role in preventing abnormal cells from becoming a tumor by inducing programmed cell death. Mutant p53 takes on oncogenic properties that endow cancer cells with a growth advantage and resistance to anti-cancer therapy. The p53 Y220C mutation is associated with many cancers, including but not limited to breast, non-small cell lung cancer, colorectal, pancreatic, and ovarian...

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that it will present new translational data at the 2021 American Association for Cancer Research (AACR) Annual Meeting taking place virtually from April 10-15, 2021. Data from Checkmate’s Phase 1b trial of CMP-001 in subjects with advanced melanoma will be presented in an oral presentation during the Clinical Trials with Novel Immuno-oncology Strategies Session.Oral Presentation Details:Title: CMP-001 demonstrates improved response in noninflamed anti–PD-1 refractory melanoma and response is associated with serum CXCL10Presenting Author: Jason Luke, MD,...

MONTREAL, March 10, 2021 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that new positive pre-clinical data on TH1902, its lead peptide-drug conjugate (PDC) for the treatment of sortilin positive (SORT1+) solid tumors, will be presented in two e-posters during AACR Annual Meeting 2021.Presentation Title: TH1902, a docetaxel peptide-drug conjugate, shows pre-clinical efficacy in several sortilin positive (SORT1+) cancersAbstract Number: 1313E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AMPresentation Title: Increasing potency of anticancer drugs through SORT1+ Technology: A new targeted approach for the treatment of ovarian and endometrial cancersAbstract...

MONTRÉAL, 10 mars 2021 (GLOBE NEWSWIRE) — Theratechnologies inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), une société biopharmaceutique commerciale axée sur le développement et la commercialisation de traitements innovateurs, a le plaisir d’annoncer que de nouvelles données précliniques positives sur le TH1902, son principal conjugué peptide-médicament (CPM) pour le traitement des tumeurs solides exprimant la sortiline (SORT1+), seront présentées par le biais de deux posters électroniques durant la réunion annuelle de 2021 de l’AACR.Titre de la présentation : TH1902, a docetaxel peptide-drug conjugate, shows pre-clinical efficacy in several sortilin positive (SORT1+) cancersNuméro du résumé : 1313Date et heure du lancement du site web des posters électroniques : Le samedi 10 avril 2021 à 8h30Titre de la présentation : Increasing...

SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that a trial-in-progress poster will be presented at the virtual AACR Annual Meeting, which is being held over two one-week periods: April 10 – 15 and May 17 – 21 2021. The poster will describe the design of the company’s ongoing Phase 1b first-in-human clinical trial evaluating ATRC-101 as monotherapy and in combination with pembrolizumab in patients with solid tumor cancers.Details of the presentation are as follows:Title: First-in-human phase 1b study of ATRC-101, a patient-derived antibody with a tumor-specific target, as monotherapy...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, today announced four preclinical poster presentations at the 2021 American Association for Cancer Research (AACR) virtual annual meeting on April 10-15, 2021.“We are pleased to present these compelling preclinical data on our four product candidates, which continue to validate our scientific platform focused on overcoming resistance in cancer,” said Lori Friedman, chief scientific officer. “In particular, we are encouraged to see our lead program ORIC-101 reversing GR-mediated resistance in a variety of tumor models and contexts. Furthermore, ORIC-533, ORIC-944 and ORIC-114 each continue to show mounting...

– Full Year Revenues of $49.2 Million (up 48.8% yoy) And Share in NPI Revenue Interests of $9.5 Million (up 387.5% yoy) totaling $58.7 (up 67.7% yoy) –– Full Year Net Income of $0.29 Per Share –– Full Year Adjusted EBITDA1of $28.7 Million, up 141.7% –– Initiates Full Year 2021 Revenue and Share in NPI Revenues Interest Guidance of $65 Million to $69 Million –LUXEMBOURG, March 10, 2021 (GLOBE NEWSWIRE) — NeoGames S.A. (Nasdaq: NGMS) (“NeoGames” or the “Company”), a technology-driven provider of end-to-end iLottery solutions, announced today financial results for the fourth quarter and fiscal year ended December 31, 2020.Moti Malul, Chief Executive Officer of NeoGames, said: “We are proud to be reporting our results for the first time as a publicly traded company. The past year was pivotal for NeoGames and the execution...

NEW YORK and SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) — Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that three abstracts have been accepted for presentation, including a late-breaker on its WEE1 inhibitor, ZN-c3, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021. The meeting will be held virtually on April 10-15 and May 17-21, 2021.“The important data we are presenting at AACR supports the ability of our Integrated Discovery Engine to develop differentiated oncology therapeutic candidates across diverse cancer targets and types,” commented Dr. Anthony Sun, Chairman and Chief Executive Officer of Zentalis Pharmaceuticals....

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced that preclinical data for RLY-4008, a potent, selective and oral small molecule inhibitor of FGFR2, has been selected for poster presentation at the upcoming virtual American Association for Cancer Research (AACR) Annual Meeting. AACR is being held April 10-15 and May 17-21. The Company anticipates disclosing initial clinical data for RLY-4008 in the second half of 2021.Poster Presentation Details:Title: RLY-4008, a novel precision therapy for FGFR2-driven cancers designed to potently and selectively inhibit FGFR2 and FGFR2 resistance mutationsAbstract Number: 1455Session Category: Experimental...